In vivo correction of anaemia in beta-thalassemic mice by gammaPNA-mediated gene editing with nanoparticle delivery by Bahal, Raman et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2016-10-26 
In vivo correction of anaemia in beta-thalassemic mice by 
gammaPNA-mediated gene editing with nanoparticle delivery 
Raman Bahal 
Yale University 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Genetics and 
Genomics Commons, Hemic and Lymphatic Diseases Commons, and the Nanomedicine Commons 
Repository Citation 
Bahal R, Greiner DL, Brehm MA, Glazer PM. (2016). In vivo correction of anaemia in beta-thalassemic mice 
by gammaPNA-mediated gene editing with nanoparticle delivery. Open Access Articles. https://doi.org/
10.1038/ncomms13304. Retrieved from https://escholarship.umassmed.edu/oapubs/2968 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
ARTICLE
Received 14 Sep 2015 | Accepted 21 Sep 2016 | Published 26 Oct 2016
In vivo correction of anaemia in b-thalassemic mice
by gPNA-mediated gene editing with nanoparticle
delivery
Raman Bahal1,*, Nicole Ali McNeer1,2,*, Elias Quijano2, Yanfeng Liu1, Parker Sulkowski1,3, Audrey Turchick1,3,
Yi-Chien Lu4, Dinesh C. Bhunia5, Arunava Manna5, Dale L. Greiner6, Michael A. Brehm6, Christopher J. Cheng2,
Francesc Lo´pez-Gira´ldez7, Adele Ricciardi1,2, Jagadish Beloor8, Diane S. Krause4, Priti Kumar8,
Patrick G. Gallagher9, Demetrios T. Braddock10, W. Mark Saltzman2, Danith H. Ly5 & Peter M. Glazer1,3
The blood disorder, b-thalassaemia, is considered an attractive target for gene correction.
Site-speciﬁc triplex formation has been shown to induce DNA repair and thereby catalyse
genome editing. Here we report that triplex-forming peptide nucleic acids (PNAs) substituted
at the g position plus stimulation of the stem cell factor (SCF)/c-Kit pathway yielded high
levels of gene editing in haematopoietic stem cells (HSCs) in a mouse model of human
b-thalassaemia. Injection of thalassemic mice with SCF plus nanoparticles containing gPNAs
and donor DNAs ameliorated the disease phenotype, with sustained elevation of blood
haemoglobin levels into the normal range, reduced reticulocytosis, reversal of splenomegaly
and up to 7% b-globin gene correction in HSCs, with extremely low off-target effects.
The combination of nanoparticle delivery, next generation gPNAs and SCF treatment may
offer a minimally invasive treatment for genetic disorders of the blood that can be achieved
safely and simply by intravenous administration.
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1 Department of Therapeutic Radiology, Yale University, New Haven, Connecticut 06520, USA. 2Department of Biomedical Engineering, Yale University,
New Haven, Connecticut 06511, USA. 3 Department of Genetics, Yale University, New Haven, Connecticut 06520, USA. 4Department of Laboratory
Medicine, Yale University, New Haven, Connecticut 06520, USA. 5 Department of Chemistry and Center for Nucleic Acids Science and Technology (CNAST),
Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA. 6 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester,
Massachusetts 01605, USA. 7 Yale Center for Genome Analysis (YCGA), Yale University, Orange, Connecticut 06477, USA. 8Department of Internal
Medicine, Section of Infectious Disease, Yale University, New Haven, Connecticut 06520, USA. 9 Department of Pediatrics, Yale University, New Haven,
Connecticut 06520, USA. 10 Department of Pathology, Yale University, New Haven, Connecticut 06520, USA. * These authors contributed equally to this
work. Correspondence and requests for materials should be addressed to P.M.G. (email: peter.glazer@yale.edu).
NATURE COMMUNICATIONS | 7:13304 | DOI: 10.1038/ncomms13304 |www.nature.com/naturecommunications 1
G
ene editing in haematopoietic stem cells (HSCs) may
provide a strategy for treatment of inherited
disorders such as sickle cell disease and b-thalassaemia.
Methods for gene editing include targeted nucleases such
as zinc-ﬁnger nucleases1 and CRISPR/Cas9 (ref. 2), short
fragment homologous recombination3 and triplex-forming
oligonucleotides4. Recent excitement has focused on CRISPR/
Cas9 technology because of facile reagent design5. However, like
zinc-ﬁnger nucleases, the CRISPR approach introduces an active
nuclease into cells, which can lead to off-target cleavage in the
genome6. As an alternative, we have pursued triplex-forming
peptide nucleic acids (PNAs) designed to bind site-speciﬁcally to
genomic DNA via strand invasion and formation of PNA/DNA/
PNA triplexes (via both Watson–Crick and Hoogsteen binding)
with a displaced DNA strand7–9. PNAs consist of a charge-
neutral peptide-like backbone and nucleobases enabling
hybridization with DNA with high afﬁnity. PNA/DNA/PNA
triplexes recruit the cell’s endogenous DNA repair systems
to initiate site-speciﬁc modiﬁcation of the genome when
single-stranded ‘donor DNAs’ are co-delivered as templates
containing the desired sequence modiﬁcation10.
Our prior work has suggested that PNA-induced genome
modiﬁcation is mediated by the nucleotide excision repair
and homology-dependent repair (HDR) pathways10,11. Both
nucleotide excision repair and HDR are high ﬁdelity pathways,
and the PNAs lack any intrinsic nuclease activity; together these
features may account for the very low frequencies of off-target
genotoxicity seen with PNA-mediated gene editing compared
with nuclease based approaches12–14. We have also recently
shown that tail-clamp PNAs (tcPNAs) with an extended
Watson–Crick binding domain can enhance gene editing
in human haematopoietic cells with increased efﬁciency and
speciﬁcity13 and that polymer nanoparticles (NPs) can effectively
deliver these molecules into human HSCs both ex vivo and in vivo
in a humanized mouse model12,15.
Here, we use next generation triplex-forming gPNAs
containing a polyethylene glycol substitution at the gamma
position for enhanced DNA binding16. Delivered via polymer
NPs, the gPNAs mediate increased gene editing in HSCs both
ex vivo and in vivo in two different mouse models, one carrying a
b-globin/green ﬂuorescent protein (GFP) fusion transgene and
the other carrying the human b-globin gene replacing the mouse
b-globin genes and containing a b-thalassaemia-associated
splicing mutation at IVS2-654 (refs 17,18). We ﬁnd that
treatment with stem cell factor (SCF), the c-Kit ligand, further
enhances PNA-mediated gene editing, an effect associated with
increased DNA repair. Treatment of thalassemic mice18 with NPs
containing gPNAs and donor DNAs, plus SCF, produced up to
7% gene editing in HSCs, with elevation of blood haemoglobin
levels for 140 days post-treatment, reduction in reticulocyte
counts and reversal of splenomegaly. gPNA treatment also
yielded gene editing in human CD34þ HSCs ex vivo at a
frequency of 5% with a single treatment, with very low off-target
effects. These results indicate that chemical advances in PNA
design and in vivo delivery via polymer NPs can mediate clinically
relevant levels of gene editing. They also identify SCF treatment
as a potential pharmacologic strategy to increase gene editing that
may be applicable not only to triplex-forming PNAs but also to
approaches such as CRISPR/Cas9.
Results
Triplex-forming PNA design for gene editing. To quantitatively
assay for gene editing, we used a mouse model with a b-globin/
GFP fusion transgene consisting of human b-globin intron 2
carrying a thalassaemia-associated IVS2-654 (C-T) mutation
embedded within the GFP coding sequence, resulting in incorrect
splicing of b-globin/GFP mRNA and lack of GFP expression19.
PNA-mediated triplex-formation induces recombination of the
genomic site with a 60-nucleotide sense donor DNA homologous
to the b-globin intron 2 sequence except for providing a wild-type
nucleotide at the IVS2-654 position. Correction of the splice-site
mutation yields expression of functional GFP (Fig. 1a)12,15,
providing a phenotypic read-out of editing quantiﬁable by ﬂow
cytometry.
We designed a series of tcPNAs to bind to polypurine stretches
in the b-globin intron near the IVS2-654 mutation (Fig. 1b). One
of the tcPNAs and a scrambled sequence control were synthesized
to contain partial substitution with a mini-polyethylene-glycol
group at the g position (MPgPNA; Fig. 1c,d) within their
Watson–Crick binding domains. We made the substitutions in
the Watson–Crick domains because in prior work gPNAs have
been shown to enhance strand invasion and DNA binding in the
Watson–Crick binding mode due to helical pre-organization
enforced by the modiﬁcation16. We hypothesized that this would
enhance the binding of the tcPNAs because strand invasion and
Watson–Crick PNA/DNA duplex formation is an important
component in the formation of PNA/DNA/PNA triplexes. Partial
substitution was performed because it is sufﬁcient to improve
binding afﬁnity and to confer helical pre-organization20.
gtcPNA4 matches the sequence of tcPNA1 except that it
contains g units at alternating positions in the Watson–Crick
domain (Fig. 1d). Scrambled gtcPNA (gtcPNA4-Scr) has the
same base composition as gtcPNA4 but a scrambled sequence.
All tcPNA oligomers were synthesized with 3 lysines at both
termini to improve solubility and increase binding afﬁnity
(Fig. 1d). Puriﬁcation and characterization of the synthesized
PNAs were performed by high-performance liquid chromato-
graphy analyses and matrix-assisted laser desorption/ionization
time-of-ﬂight, respectively (Supplementary Fig. 1 and
Supplementary Table 1). Gel shift assays to assess the binding
of the tcPNAs to DNAs containing the respective target
sequences showed that all bound speciﬁcally to their target sites
(Supplementary Fig. 2A). No binding was seen in the case of the
scrambled sequence gtcPNA4-Scr.
In prior work, we showed that poly(lactic-co-glycolic acid)
(PLGA) NPs can effectively deliver PNA/donor DNA combina-
tions into primary human and mouse haematopoietic cells with
essentially no toxicity12,14,21. Here, tcPNAs and donor DNAs, at a
molar ratio of 2:1, were incorporated into poly(lactic-co-glycolic
acid) (PLGA) NPs. The NP formulations were evaluated by
scanning electron microscopy and dynamic light scattering. All
the NPs exhibited sizes within the expected range (Fig. 1e and
Supplementary Fig. 2B,C) and showed uniform charge
distribution (Supplementary Fig. 2D). Nucleic acid release proﬁles
showed that g modiﬁcations did not impair release from NPs
(Supplementary Fig. 2E).
Ex vivo gene editing in bone marrow cells. Bone marrow (BM)
cells harvested from b-globin/GFP mice were treated ex vivo with
PLGA NPs containing tcPNA1/donor DNA, tcPNA2/donor DNA
and tcPNA3/donor DNA. After 48 h, the percentage of GFPþ
(corrected) cells was quantiﬁed via ﬂow cytometry (Fig. 1f). The
higher gene editing activity of tcPNA1 is likely due to its longer
Hoogsteen binding domain, an effect that we have previously
observed13. NPs containing the g-substituted tcPNA (gtcPNA4)
and donor DNA yielded signiﬁcantly higher gene modiﬁcation
(1.62%; Fig. 1g and Supplementary Fig. 3A), showing that the
MPg substitutions confers increased biological activity that
correlates with their improved binding properties. NPs with the
gtcPNA4–Scr produced no modiﬁcation (Fig. 1g).
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Figure 1 | Gene editing using cPNAs in mouse bone marrow. (a) Strategy for targeted correction of a b-globin gene IVS2-654 (C-4T) mutation in
b-globin/GFP transgenic mice using triplex-forming tail-clamp PNAs and donor DNAs. (b) tcPNA and gtcPNAs designed to bind to homopurine regions
within intron 2 of the human b-globin gene near IVS2-654 (C-4T). (c) DNA, unmodiﬁed PNA and MPgPNA. (d) tcPNAs and gtcPNAs to bind to the
positions indicated in B. gtcPNA4-Scr is a scrambled version of gtcPNA4. Bold/underline indicates gPNA residues. K indicates lysine; J, pseudoisocytosine
(for c) for pH-independent triplex formation. O, 8-amino-2,6,10-trioxaoctanoic acid linkers connecting the Hoogsteen and Watson–Crick domains of
the tcPNAs. (e) Scanning electron microscope images of nanoparticles. Scale bar, 2.0 mm. (f) Gene correction of the IVS2-654 (C-4T) mutation within the
b globin/GFP fusion gene in mouse BM cells treated ex vivo with NPs containing the indicated tcPNAs and donor DNA. %GFPþ was determined by ﬂow
cytometry and indicates successful gene editing. Data are mean±s.e., n¼ 3; statistical analysis by Student’s t-test, **Po0.005. (g) %GFPþ cells in mouse
BM after ex vivo treatment with NPs containing tcPNA1, gtcPNA4 or gtcPNA4-Scr, plus donor DNAs. Data are mean±s.e.m., n¼ 3; analysis by Student’s
t-test, *Po0.05. (h,i) Quantiﬁcation of gH2AX foci by immune ﬂuorescence microscopy, indicative of DNA DSBs in primary ﬁbroblasts (from the
b-globin/GFP transgenic mice) either untreated or treated with 5 Gy of IR, blank NPs, NPs containing gtcPNA4 and donor DNA, lipofectamine alone,
lipofectamine transfection of a Cas9 expression vector, lipofectamine transfection of a Cas9 vector and a separate guide RNA expression vector (targeting
the same site in b-globin sequences as gtcPNA4; Cas9þ gRNA), or transfection of a vector containing both Cas9 and guide RNA (Cas9 and gRNA).
Quantiﬁcation as per cent of cells with 15 or more foci (h) or average number of foci per cell (i). 100 cells were counted per condition, data are
mean±s.e.m, n¼ 3; analysis by Student’s t-test, *Po0.05.
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BM cells treated with either blank NPs or NPs containing
gtcPNA4/donor DNA were plated in methylcellulose medium
supplemented with cytokines for growth of granulocyte/
macrophage colonies (colony-forming unit (CFU)-G, CFU-M
and CFU-GM) or combined colonies (CFU-GEMM, granulocyte,
erythroid, monocyte/macrophage and megakaryocyte). The
two sets of treated cells formed myeloid and erythroid
colonies at similar frequencies (Supplementary Fig. 3B,C),
suggesting that treatment with gtcPNA4 and donor DNA does
not impair the ability of the progenitor cells to proliferate
and differentiate. Sequencing analysis of genomic DNA
from selected GFP-positive methylcellulose colonies conﬁrmed
the presence of the targeted gene modiﬁcation in the b-globin/
GFP transgene at the IVS2-654 base pair (Supplementary
Fig. 3D). Also, there was no induction of the inﬂammatory
cytokines in the treated BM cells (Supplementary Fig. 3E),
consistent with prior work with NPs containing standard
PNAs12,14,21.
In assays for genotoxicity, there was no detectable increase in
DNA double-strand breaks (DSBs) in the BM cells treated with
gtcPNA4/donor DNA-containing NPs compared with blank
NPs based on a single-cell gel electrophoresis assay (Comet
assay; Supplementary Fig. 4A). We also assayed for DSBs by
measuring the production of gH2AX foci. gH2AX foci are
detected in nuclei by immune ﬂuorescence and document a
chromatin modiﬁcation that occurs upon DSB formation via
DNA damage response signalling22. Treatment of the BM cells
with NPs containing gtcPNA4/donor DNA did not produce any
gH2AX foci above the low background that is seen in untreated
cells (assayed by ﬂow cytometry as shown in Supplementary
Fig. 4B). Treatment of the cells with 5 Gy of ionizing radiation
(IR) was included as a positive control for induction of DSBs.
We also used primary ﬁbroblasts from the mice for this assay,
since adherent cells facilitate more robust quantiﬁcation of foci
by immune ﬂuorescence microscopy. Treatment of the
ﬁbroblasts with NPs containing gtcPNA4/donor DNA again did
not produce gH2AX foci above the low background in untreated
or blank NP treated cells (quantiﬁed in Fig. 1h as per cent of
cells with more than 15 foci and in Fig. 1i as average number of
foci per nucleus, with corresponding immune ﬂuorescence images
of foci shown in Supplementary Fig. 5). For comparison,
transfection of a vector expressing the Cas9 nuclease yielded an
increase in gH2AX foci (Fig. 1h,i). Co-expression of a guide RNA
designed to bind to the same sequence in the b-globin gene as
gtcPNA4 (either via the same plasmid or via a plasmid separate
from the Cas9 vector) reduced the number of induced DSBs, but
to a level that was still above background (Fig. 1h,i and
Supplementary Fig. 5).
Elevated gene editing by ctcPNAs in CD117þ cells. Previous
work suggested that there might be increased PNA-mediated
editing in colony-forming progenitors12. To test this, we treated
whole BM cells with either blank NPs, NPs containing
tcPNA1/donor DNA, or NPs containing gtcPNA4/donor DNA.
Two days later, ﬂow cytometry was performed to assess the
frequency of GFPþ cells within selected sub-populations.
CD117þ cells showed elevated gene editing compared with the
total CD45þ cell population (Fig. 2a), with 8.6% in CD117þ
cells after a single treatment with gtcPNA4/donor DNA NPs. The
less potent tcPNA1/donor DNA NPs still yielded an elevated
correction frequency of 2.1% in CD117þ cells compared with
the total BM (although fourfold lower than gtcPNA4). Next, we
sorted for CD117þ cells before treatment with the NPs (Fig. 2b).
An elevated percentage of modiﬁcation (7.2%) was again seen
after a single treatment (Fig. 2b).
The c-Kit pathway mediates increased gene editing. CD117
(also known as mast/stem cell growth factor receptor or
proto-oncogene c-Kit protein) is a receptor tyrosine kinase
expressed on the surface of haematopoietic stem and progenitor
cells and other cell types. SCF, the ligand for c-Kit, causes
dimerization of the receptor, activating its kinase activity to
trigger signalling pathways that impact survival, proliferation and
differentiation.
We asked whether c-Kit-dependent signalling is required for
elevated gene correction or whether CD117 simply serves as a
marker for the increased susceptibility. First, we tested for gene
editing in pre-sorted CD117þ cells treated with or without the
c-Kit ligand, SCF, and we observed a signiﬁcant increase in
gtcPNA4/donor DNA-mediated gene editing (up to almost 15%)
in the SCF-treated cells (Fig. 2c and Supplementary Fig. 6).
We next assayed for gtcPNA4/donor DNA NP-mediated gene
editing in pre-sorted CD117þ cells in the presence or absence of
kinase inhibitors (Fig. 2d). Dasatinib, which inhibits the c-Kit
kinase in addition to the BCR/Abl and Src kinases, reduced the
gene editing from 7 to 2.0%. Inhibitors of factors downstream of
c-Kit, including mitogen/extracellular signal-regulated kinase
(MEK; Binimetinib; MEK162) and phosphatidylinositol-3-kinase
(BKM120), also decreased gene editing in CD117þ cells to 2.6
and 4.1%, respectively (Fig. 2d).
We also tested tcPNA1 (no gamma substitutions) for gene
editing in pre-sorted CD117 cells treated or not with SCF. We
found that SCF boosted tcPNA1/donor DNA gene editing up to
5% versus about 1.5% without SCF (Supplementary Fig. 7). While
substantial, this was threefold lower than the almost 15%
frequency seen with the gtcPNA4/donor DNA NPs in
conjunction with SCF treatment of the pre-sorted CD117 cells
(Fig. 2c). Overall, these results indicate that the SCF/c-Kit
signalling can enhance gene editing and identify SCF as a
potential agent to stimulate PNA-mediated gene modiﬁcation. In
addition, the results further show that gtcPNAs provide increased
gene editing potential as compared with regular tcPNAs.
Increased DNA repair gene expression upon activation of c-Kitþ .
To explain the increased gene editing in CD117 cells, we tested
whether CD117 might be associated with differential uptake of
the NPs. However, there were no differences in uptake across
several BM cell sub-populations (Supplementary Fig. 8). Next, we
examined gene expression patterns in the c-Kitþ cells to test the
hypothesis that there might be increased DNA repair gene
expression. RNA from sorted CD117þ and CD117 cells from
the b-globin/GFP mice was analysed using Illumina arrays
(Supplementary Fig. 9A–C). We found that numerous DNA
repair genes, including BRCA1, BRCA2, Rad51, ERCC2, XRCC2
and XRCC3, showed higher levels of expression in CD117þ cells
(Supplementary Figs 10 and 11a)., The elevated expression two
genes likely to play a role in PNA-induced recombination, BRCA2
and Rad51, was conﬁrmed in CD117þ cells by quantitative PCR
with reverse transcription (Supplementary Fig. 11B,C) and by
western blot (Supplementary Fig. 11D). We went on to test
whether SCF treatment could further increase DNA repair
gene expression. Gene expression proﬁling showed additional
up-regulation of numerous DNA repair genes by SCF treatment
(Fig. 2e and Supplementary Fig. 12A,B).
Because SCF, as a stimulatory cyctokine, would be expected to
impact the cell cycle in c-Kitþ cells and because HDR gene
expression is known to be elevated in S-phase, we also measured
the effect of SCF on cell cycle phase distribution in the pre-sorted
CD117 cells. We found that there was a 9% increase in the per
cent of cells in S-phase at 48 h after SCF treatment as compared
with no SCF treatment (Supplementary Fig. 13). Hence, some
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component of the SCF effect on DNA repair genes could be an
indirect effect of cell cycle changes.
The c-Kit pathway induces functionally elevated DNA repair.
To test whether the above increases in DNA repair gene
expression could be correlated with functional differences in
DNA repair, we used a luciferase-based assay to quantify repair of
DNA DSBs by HDR. In this assay, repair of a DSB in a reporter
plasmid via intramolecular homologous recombination creates
(‘reactivates’) a functional luciferase gene (Fig. 2f), and so the
assay provides a measure of HDR capacity (validation of the assay
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Figure 2 | The SCF/c-Kitþ pathway promotes gene editing and DNA repair. (a) %GFP expression in treated mouse BM cells expressing the indicated
cell surface markers. Total BM was treated with NPs containing either tcPNA1/donor DNA or gtcPNA4/donor DNA, cells were stained using antibodies
speciﬁc for the indicated markers and assayed by ﬂow cytometry for marker and GFP expression. Data are mean±s.e.m, n¼ 3; statistical analysis by
Student’s t-test, *Po0.05. (b) %GFP expression in pre-sorted CD117 (c-Kitþ ) cells treated with either NPs carrying gtcPNAs and donor DNAs or blank
NPs. Data are mean±s.e.m., n¼ 3; statistical analysis by Student’s t-test, **Po0.005. (c) %GFP expression in pre-sorted CD117þ cells treated with NPs
containing gtcPNA4/donor DNA with or without prior treatment with the c-Kit ligand, SCF. Data are mean±s.e.m., n¼ 3; statistical analysis by Student’s
t-test, *Po0.05. (d) %GFP expression in pre-sorted CD117þ cells treated with NPs containing gtcPNA4/donor DNA in the presence or absence of c-Kit
pathway kinase inhibitors: dasatinib (inhibits c-Kit), MEK162 (inhibits MEK, MEK) and BKM120 (inhibits phosphatidylinositol-3-kinase). Data are
mean±s.e.m, n¼ 3; statistical analysis by Student’s t-test, *Po0.05. (e) Heat map showing upregulated genes involved in DNA repair in CD117þ cells
with or without SCF treatment; rows are clustered by Euclidean distance measure. (f) Reporter gene assay for HDR activity in CD117 cells in the presence or
absence of c-Kit pathway kinase inhibitors: dasatinib, MEK162 and BKM120 (as above). Inset shows diagram of the luciferase reporter assay for repair of a
nuclease-indcued DSB by HDR. Luciferase expression occurs only after homologous recombination and is scored as % reactivation of the DSB-damaged
plasmid, normalized to a transfection control. Data are mean±s.e.m., n¼ 3; statistical analysis by Student’s t-test, ***Po0.005. (g) HDR assay in CD117þ
cells with or without the addition of SCF. Data are shown as mean±s.e.m., n¼ 3; statistical analysis by Student’s t-test, ***Po0.005 and ****Po0.0005.
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is shown in Supplementary Fig. 14). The results show increased
HDR in CD117þ compared with CD117 cells (Fig. 2f). HDR
in CD117þ cells was diminished by the kinase inhibitors
MEK162, BKM120 and dasatnib (Fig. 2g); conversely, it was
boosted by SCF treatment (Fig. 2g). These results indicate that
c-Kit signalling increases HDR.
In vivo gene editing by PNA/DNA NPs given intravenously.
We next tested the potential for in vivo gene editing in the
b-globin/GFP transgenic mice by simple intravenous injection of
NPs containing tcPNA1/donor DNA or gtcPNA4/donor DNA,
and we further asked whether the editing could be enhanced by
SCF treatment. Mice were treated with a single dose of 4mg NPs,
and 2 days later we analysed gene editing in BM and spleen.
Some mice also received murine SCF (220 mg kg 1) given by
intraperitoneal injection 3 h before the NP injection (Fig. 3a,b,
with experimental scheme shown in Supplementary Fig. 15A).
In vivo gene editing was scored by GFP expression in
marker-sorted cell populations from BM and spleen (Fig. 3a,b).
We observed an average ofB0.2% gene editing in the CD117 BM
cells from tcPNA1/donor DNA and SCF-treated mice (Fig. 3a).
Two to threefold higher levels of gene editing were seen in
CD117þ cells from BM of the gtcPNA4/donor DNA and
SCF-treated mice, with frequencies in the range of 1% in several
mice, and average frequencies in the 0.5% range. Similar
frequencies were seen in spleen (Fig. 3b).
We conﬁrmed these results by performing deep sequencing
analysis on DNA from CD117þ cells isolated from BM and
spleen of treated mice (Fig. 3c and Supplementary Fig. 15A),
revealing gene editing frequencies in the range of 0.2% in the BM
of mice treated with gtcPNA4/donor DNA NPs without SCF and
0.6% in mice receiving SCF along with the gtcPNA4/donor DNA
NPs (in a single treatment in each case), consistent with the
frequencies of gene correction quantiﬁed by GFP expression.
Deep sequencing was also used to assess off-target effects in the
BM cells of the mice that were treated with SCF and gtcPNA4
and donor DNA NPs (Table 1). By BLAST analysis, we identiﬁed
seven off-target sites with partial homology to the target site of
gtcPNA4 in b-globin intron 2. Extremely low frequencies of
off-target effects were found in the gtcPNA4/donor DNA treated
mice, with six sites showing no detectable sequence changes out
of millions of reads and two sites showing modiﬁcation
frequencies of only 0.0074 and 0.00018% compared with 0.56%
at the targeted b-globin site (Table 1). The overall off-target
modiﬁcation frequency at all seven sites combined was 0.00034%,
1,647-fold lower than the frequency of the targeted gene editing.
We also performed cytokine array analyses on plasma derived
from mice 48 h after treatment with gtcPNA4/donor DNA NPs .
There were no detectable increases in levels of any of the
cytokines measured compared with untreated mice (Fig. 3d), with
lipopolysaccharide treatment as a positive control showing
signiﬁcantly higher levels of multiple cytokines that were off the
scale of the graph (Supplementary Fig. 16). In a separate
experiment, mice were treated with gtcPNA4/donor DNA NPs
on day 1 and again 3 months later, followed by cytokine analysis
of peripheral blood, again showing minimal immune or
inﬂammatory response (Supplementary Fig. 17A,B).
In vivo correction of a b-thalassaemia mutation in mice. We
next tested for correction of a human b-thalassaemia mutation in
a mouse disease model, using a transgenic mouse line in
which the two (cis) murine adult beta globin genes were
replaced with a single copy of the human b-globin gene with the
same thalassaemia-associated IVS2-654 mutation as above18.
Homozygous mice do not survive, and heterozygotes have a
moderate form of b-thalassaemia, with haemolytic anaemia,
microcytosis and other erythrocyte morphologies reﬂecting
reduced amounts of mouse b-globin and no human
b-globin17,18, consistent with b-thalassaemia. Treatment groups
included (1) blank NPs; (2) SCF alone (no NPs); (3) SCF plus
gtcPNA4/donor DNA NPs; and (4) SCF plus gtcPNA4-Scr/donor
DNA (experimental scheme is shown in Supplementary Fig. 15B).
We conducted two otherwise identical replicate experiments
except that, in one, the complete blood count (CBC) analyses
were continued for 75 days after the last treatment, and in the
other for 140 days. In both cases, each treatment group consisted
of six mice, and each mouse received four treatments at 2 day
intervals at the beginning of the experiment as indicated in
Supplementary Fig. 15B. Some animals were maintained long-
term for serial CBC analyses; others were killed at intermediate
time points for analysis of spleen size and architecture and for
deep sequencing of BM-derived cells.
Blood smears at day 0 (before treatment) and at day 36 after
the last treatment (Fig. 4a) showed marked improvement in RBC
morphology on day 36 in the gtcPNA4/donor DNA treated
mice but not in the mice treated with either blank NPs, SCF alone
or SCF plus gtcPNA4-Scr/donor DNA. CBC analyses performed
on blood samples taken at 30, 45, 60, 75, 90 and 140 days
post-treatment from mice in each group showed persistent
correction of the anaemia based on blood haemoglobin levels in
the mice treated with SCF plus the gtcPNA4/donor DNA NPs
(Fig. 4b), with elevation of the blood haemoglobin levels into the
normal range. The anaemia was not improved in any of the
controls. We also observed reduced reticulocyte counts in mice
treated with SCF plus the gtcPNA4/donor DNA NPs but not in
the mice treated with blank NPs (Fig. 4c). In addition, the
gtcPNA4/donor DNA treated mice also showed reduced
splenomegaly at 36 days post-treatment (Fig. 4d).
Consistent with reduced splenomegaly, histologic examination
of spleens from mice on days 36 and 75 showed substantially
improved splenic architecture speciﬁcally in the gtcPNA4/donor
DNA treated mice (Fig. 4e and Supplementary Figs 18 and 19).
The regular splenic pattern of white pulp (lymphoid follicles)
surrounded by rims of red pulp is disrupted in the b-thalassemic
animals due to extramedullary haematopoiesis, causing an
expansion in red pulp (causing the splenomegaly) and disruption
of the white pulp. The CD61 and Ecad immunohistochemical
stains (Supplementary Fig. 18) highlight the increased cellularity
characteristic of extramedullary haematopoiesis and demonstrate
that the expanded red pulp includes elevated megakaryocytes and
erythroid precursors, respectively. This increased cellularity is
substantially ameliorated in the gtcPNA4/donor DNA treated
mice (Supplementary Fig. 18).
Deep sequencing analyses were performed on total BM cells of
mice on day 36 post-treatment. Correction of the targeted
mutation was seen at a frequency of almost 4% in the gtcPNA4/
donor DNA treated group (Fig. 5a; combined analysis of 3 mice),
whereas no correction was seen in the mice treated with blank
NPs (Fig. 5a). Deep sequencing was also used to assess off-target
effects in the BM cells at seven sites with partial homology
to the binding site of gtcPNA4 in the b-globin gene. We found
extremely low frequencies of off-target effects in the gtcPNA4/
donor DNA-treated thalassemic mice (Table 2). The overall
off-target modiﬁcation frequency was 0.0032%, 1,218-fold lower
than the frequency of b-globin gene editing.
In addition, we sorted the cells from the BM of the SCF and
gtcPNA4/donor DNA NP treated mice (the BM was collected 65
days after the last treatment) for markers consistent with several
stem/progenitor cell populations23, and we again performed deep
sequencing of the b-globin gene. This revealed evidence for gene
editing at a frequency of 6.9% in Lin-Sca1þ cKitþ CD150þ
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CD135-cells (Fig. 5a and Supplementary Fig. 20), a population
that is highly enriched for long-term HSCs. We also observed
gene editing in multiple other progenitor populations (Fig. 5a).
We also noted that the b-thalassemic animals had
elevated levels of CD117þ cells in their BM compared
with the phenotypically normal b-globin/GFP transgenic mice
(Supplementary Fig. 21), indicative of the stress erythropoeisis in
these animals. We also found that the proportion of CD117þ
cells was further increased by SCF treatment. These elevated
levels of CD117þ cells, and the stress erythropoeisis that
underlies them, could explain, in part, the increased susceptibility
to gene editing in the thalassemic mice.
Gene editing by ctcPNAs in CD34þ human HSCs. We next
tested the gene editing potential of gtcPNA4/donor DNA NPs in
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Figure 3 | SCF treatment of mice enhances in vivo gene editing by ctcPNAs and donor DNAs. (a,b) b-globin/GFP transgenic mice (n¼ 6 mice per group)
were injected or not (as indicated) with 220 mg kg 1 of SCF i.p. followed by a single treatment of 4mg of NPs injected intravenously. Each group received
either blank NPs, NPs containing tcPNA1 and donor DNA, or NPs containing gtcPNA4 and donor DNA, with or without SCF. Two days later, BM and spleen
cells were harvested for analysis by ﬂow cytometry and deep sequencing. Frequencies of gene editing in haematopoietic cell sub-populations identiﬁed by
the indicated cell surface markers from BM (a) and spleen (b) of mice treated with the indicated NPs and with or without pre-treatment with SCF. Each
data point represents analysis of cells from a single mouse. Horizontal bars indicate mean, statistical analysis by Student’s unpaired t-test, *Po0.05.
(c) Deep-sequencing analysis to quantify the frequency of targeted gene editing in vivo in CD117þ cells from BM and spleen of b-globin/GFP mice treated
as above. Error bars indicate standard error of proportions. (d) Analysis of cytokine levels, as indicated, in blood of either untreated, blank NP treated, or
gtcPNA4 and donor DNA NP treated mice at 48h post treatment. Data are shown as mean±s.e.m., n¼ 3.
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human CD34þ cells. Because we did not have cells from a
thalassemic patient, we obtained human CD34þ cells from
healthy donors from a cell bank. Consequently, we used a
modiﬁed donor DNA designed to introduce a mutation at posi-
tion IVS2-654 rather than correct it. One day after the CD34þ
cells were thawed into stem cell medium, they were treated either
with blank NPs or with NPs containing gtcPNA4/donor DNA
plus SCF. Two days later, we performed deep sequencing,
revealing b-globin gene editing at position IVS2-654 at a
frequency of 5.0% (Fig. 5b,c and Table 3). Six off-target sites with
partial homology to the binding site of gtcPNA4 in the b-globin
gene were also analysed, and extremely low off-target frequencies
were found in two of the sites sites (0.000017 and 0.000055%),
with four sites showing no detectable sequence changes out of
millions of reads (Table 3). Combined, we saw off-target
mutations at an overall frequency of only 0.000012%, more
than 400,000-fold lower than the 5% frequency of editing in
the targeted b-globin gene. In addition, cytokine array analysis of
supernatant taken from the treated CD34þ cells showed a
minimal cytokine response (Supplementary Fig. 22).
We also performed a transplantation experiment in which
human CD34þ cells that were treated ex vivo with gtcPNA4/
donor DNA NPs and SCF were then transplanted into NOD-scid
IL2rgnullmice. Eight weeks later, human CD34þ cells were
isolated from the BM of the mice and deep sequencing was
performed to measure the presence of gene editing in the b-globin
gene (Fig. 5b). We found that 3.4% of b-globin gene alleles showed
the introduced mutation at position IVS2-654 (Fig. 5c).
Discussion
In the work reported here, we developed a gene editing strategy to
correct a thalassaemia-associated mutation in the human b-globin
gene and tested it in an established rodent model of human
b-thalassaemia. Our results demonstrate that chemically modiﬁed,
triplex-forming gPNAs and donor DNAs delivered intravenously
via polymer NPs, and given in combination with SCF treatment,
can mediate gene editing in vivo at a level sufﬁcient to ameliorate
the disease phenotype in the mice. We observed sustained
reversal of the anaemia for up to 140 days post treatment,
with normalization of serum haemoglobin concentrations and
suppression of the reticulocytosis. We also saw a morphologic
improvement in RBC cytology, along with reduced extramedullary
haematopoiesis and reduction in splenomegaly. These ﬁndings
suggest that our approach has the potential to yield a signiﬁcant
clinical response that could relieve the morbidity and mortality
associated with b-thalassaemia.
There are two key advances for gene editing in this work.
One is the incorporation of next generation PNA chemistry by
substitution at the gamma position to enhance the binding
properties of the PNAs. The second is the ﬁnding that the SCF/c-
Kit pathway promotes increased gene editing by triplex-forming
PNAs and donor DNAs. Upon ex vivo treatment of BM cells
with gPNAs, the gene editing frequency in c-Kitþ cells was as
high as 8%, 3–4-fold higher than with unmodiﬁed PNAs. The
combination of SCF treatment with the gPNAs yielded even
higher frequencies in the c-Kitþ cells, with just over 15% in a
single treatment. In vivo, treatment of transgenic mice carrying a
b-globin/GFP reporter transgene by i.p. injection of SCF followed
by intravenous administration of NPs containing gPNAs and
donor DNAs yielded gene editing in CD117þ cells at frequencies
up to 1% in a single treatment. In the thalassemic mouse model,
simple intravenous injection of gPNA/donor DNA NPs, plus SCF
given i.p., resulted in a gene editing frequency of almost 4%
in total BM cells (and 6.9% in Lin-Sca1þ cKitþ CD150þ
CD135- cells, representing a sub-population of putative HSCs)
and produced sustained amelioration of the disease phenotype,
achieved in a minimally invasive manner without the need for
stem cell harvest or transplantation.
Similarly, we achieved a frequency of 5% gene editing at the
endogenous b-globin gene in human CD34þ haematopoietic
progenitor cells treated once with SCF and gPNA/donor
DNA NPs ex vivo, and we showed that these cells can engaft
into NOD-scid IL2rgnull mice with persistent evidence of gene
editing, supporting the eventual translatability of our approach to
individuals with thalassaemia.
Importantly, in a series of assays for haematopoietic colony
formation, for induction of inﬂammatory cytokines, for
generation of strand breaks and for off-target mutagenesis, there
was essentially no measurable cellular toxicity and very low
off-target effects from the gPNA-containing NPs in either the
mouse or human cells. In the human CD34þ cells, the frequency
of off-target mutations at the 6 most closely homologous sites was
0.000012%, a value more than 400,000-fold lower than the gene
editing frequency of 5%, providing a possible safety advantage
relative to other gene editing approaches6.
Two recent publications used either TALENs or CRISPR/Cas9
for gene editing in cell culture of human iPS cells carrying the
same IVS2-654 thalassaemia-associated b-globin mutation site as
studied here24,25. These publications achieved higher editing
frequencies of 33% by TALENS and 12.3% by CRISPR/Cas9 in
one report24 and 16.7% by CRISPR/Cas9 in the other25,
compared with our editing frequency in human CD34þ cells
Table 1 | Off-target effects in bone marrow cells following intravenous treatment of b-globin/GFP mice with gtcPNA4/donor
DNA NPs.
Gene locus Sequences of partial homology
(50–30)
Size of region
sequenced
Alleles
sequenced
Number
modiﬁed
Frequency
(%)
b-globin TGCCCTGAAAGAAAGAGA 128 1,399,786 78,833 0.56
Vascular cell adhesion protein
precursor 1
AGCCCTGAAAGAAAGAGA 111 480,013 0 0
Polypyrimidine tract binding protein GAACCTGAAAGAAAGAGA 101 349,723 26 0.0074
Protocadherin fat 4 precursor CACCCTGAAAGAAAGAAG 115 73,245 0 0
Olfactory receptor 266 AAGCCTGAAAGAAAGATT 172 1,092,990 2 0.00018
Syntaxin binding protein AGAAATGAAAGAAAGAGA 150 2,478,636 0 0
Muscleblind like protein GGTGGTGAAAGAAAGAGA 165 2,331,971 0 0
Ceruloplasmin isoform AGGACTGAAAGAAAGAGT 154 1,390,439 0 0
Total off-target 8,197,017 28 0.00034
The top seven gene loci in the mouse genome with partial homology to the 18 bp gtcPNA4 target site in b-globin intron 2 were identiﬁed, with the sequences as indicated. b-globin/GFP mice were treated
with SCF followed by intravenous infusion with NPs containing gtcPNA4/donor DNA, and genomic DNA from c-Kitþ BM cells was subject to deep sequencing analysis at these loci. The size of the
region sequenced around each site is listed, along with the number of alleles sequenced and the number of alleles with modiﬁed sequences.
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of 5% (albeit a different cell type). With respect to off-target
effects, these publications used a PCR-based T7E1 assay, and so
quantitative comparisons with our deep sequencing results are
not possible. Also, these publications did not test their approaches
in vivo, and so we cannot make comparisons to our in vivo results
in the thalassemic mice.
CD117 is the product of the c-Kit gene and is a receptor
tyrosine kinase that mediates downstream signalling. Our results
suggest that activation of this pathway promotes gene editing.
Mechanistically, we observed elevated DNA repair gene
expression in CD117 cells, including factors that may play a role
in triplex-induced gene editing4,10,26,27. Importantly, we show
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Figure 4 | Correction of anaemia in thalassemic mice by NPs containing ctcPNA and donor DNA. (a) Blood smears from wild-type and thalassemic mice
obtained pre-treatment or 36 days after in vivo treatment with blank NPs, SCF alone, SCF plus scrambled gtcPNA4-Scr/donor DNA NPs or SCF plus
gtcPNA4/donor DNA NPs. NPs were given i.v.; SCF i.p. The untreated group (and control animals) exhibit extreme poikilocytosis as well as numerous
target cells, cabot rings, anisochromasia and ovalocytosis, all changes characteristic of b-thalassemia. Treatment with gtcPNA4/donor DNA and SCF
ameliorates the poikilocytosis and yields a reduction in anisocytosis, ovalocytosis and target cells suggestive of reduced alpha-globin precipitation in the
RBCs. Scale bar, 1.0mm. (b) Blood haemoglobin levels of thalassemic mice treated with blank NPs, SCF plus scrambled gtcPNA4-Scr/donor DNA NPs, or
with SCF plus gtcPNA4/donor DNA NPs performed at the indicated number of days after treatment, up to 140 days. Data are presented as box and whisker
plots showing the median and quartile range within each group over time (n¼6 per group). Only the SCF plus gtcPNA4/donor DNA-treated mice achieved
and maintained haemoglobin levels within the normal range during the duration of the experiment, reﬂecting the increased haemoglobin stability conferred
by the gene editing. Horizontal bars within the boxes indicate mean; statistical analysis by Student’s unpaired t-test, *Po0.05. (c) Reticulocyte counts
(% of total RBCs) calculated in blood smears from thalassemic mice treated with either blank NPs or with NPs containing and gtcPNA4/donor DNA plus
SCF on days 0 and 36 post treatment. Data are mean±s.e.m., n¼ 3; statistical analysis by Student’s t-test, *Po0.05. (d) Images of spleens from wild-type
mice or thalassemic mice treated with blank NPs, SCF alone, SCF plus scrambled gtcPNA4-Scr/donor DNA NPs or SCF plus gtcPNA4/donor DNA NPs at
36 days after the last treatment. Average spleen weights (with standard errors, n¼ 3; except for wild-type, where n¼ 1) are listed below the images.
Splenomegaly is corrected only by SCF plus gtcPNA4/donor DNA treatment. Scale bar, 1.0 cm. (e) Histopathologic analysis of spleen sections from
wild-type mice and from thalassemic mice obtained 36 days after treatment with blank NPs or SCF plus gtcPNA4/donor DNA NPs. Haematoxylin and eosin
stain (H&E), 40 magniﬁcation. Scale bar, 10.0mm. Additional images of spleens from other treatment groups and with additional stains are presented in
Supplementary Figs 17 and 18.
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that CD117þ cells show functional increases in DNA repair and
that treatment with SCF produces further increases.
The 4% frequency of gene editing in total BM cells (and 6.9% in
Lin-Sca1þ cKitþ CD150þ CD135- putative HSCs) achieved in
the thalassemic mice was sufﬁcient to achieve a clear improvement
in phenotype. That gene correction at these frequencies could
confer a phenotypic impact is consistent with transplantation
studies in thalassemic mice and in patients in which mixed
chimerism at one ratio of wild-type donor to thalassemic recipient
cells in the marrow has produced much higher proportions of
donor RBCs in the periphery28,29. This effect has been attributed to
increased survival of genetically corrected erythroblasts during
erythropoiesis, decreased ineffective erythropoiesis and increased
survival in the circulation of corrected erythrocytes relative to
thalassemic RBCs30.
Overall, our results provide motivation for further
development of NP-mediated delivery of gPNAs and donor
DNAs as a possible therapeutic strategy to achieve in vivo gene
editing for treatment of human genetic disorders. The work here
demonstrates gene editing in BM, but other work from our group
has shown that NP delivery of PNAs to lung airway epithelia is
also possible to achieve correction of the CFTR gene mutation
associated with cystic ﬁbrosis31,32. In this regard, the effect of SCF
on gene editing in BM raises the possibility that other cytokines
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Figure 5 | Gene editing in mouse BM stem cell populations in vivo and human CD34þ cells ex vivo. (a) Thalassemic mice were treated with either blank
NPs or NPs containing gtcPNA4/donor DNA plus SCF (four doses at 2-day intervals as in Fig. 4). Deep sequencing analysis was performed to measure
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combined analysis of BM from n¼ 3 mice in each group. Data are mean±s.e.m., n¼ 3; statistical analysis by Student’s t-test, *Po0.05. (b) Schematic
showing experimental design in which human CD34þ cells were treated ex vivo with either blank NPs or with gtcPNA4/donor DNA NPs plus SCF. Treated
cells were either harvested 2 days later for deep sequencing analysis of gene editing in the b-globin gene or were transplanted into NOD-scid IL2rgnullmice.
Eight weeks after transplantation, BM cells were harvested from the mice and human CD34þ cells were isolated, followed by deep sequencing of the the
b-globin gene alleles. (c) Deep sequencing results to quantify b-globin gene editing in either pre-transplanted human CD34þ cells or in human CD34þ
cells that were harvested from NOD-scid IL2rgnull mice 8 weeks after transplant, as described in b. Data are mean±s.e.m., n¼ 3 statistical analysis by
Student’s t-test, *Po0.05.
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or growth factors could similarly serve to boost gene editing
potential not only in BM but also in other tissues. In addition,
the ability of SCF (which is an established activator of HSCs and
is in clinical use) to stimulate gene editing by triplex-forming
PNAs may also be applicable to other editing methods, such as
CRISPR/Cas9.
Further improvements in PNA-mediated gene editing are still
possible via additional PNA chemical modiﬁcations. Most
encouraging at this point, however, is that even though gPNAs
show improved gene editing potency, the off-target effects in the
genome remain extremely low. This is in accordance with the lack
of intrinsic nuclease activity in PNAs, and reﬂects the mechanism
of triplex-induced gene editing, which creates an altered helix that
engages endogenous DNA repair pathways.
Methods
Oligonucleotides. All MPgPNA monomers were prepared from Boc-(2-(2-meth-
oxyethoxy)ethyl)-L-serine as a starting material by a series of multistep synthetic
procedures including reduction, mitsunobu reaction, nucleobase (A,C,G and T)
conjugation and then ester cleavage. At each step the respective product was puriﬁed
by column chromatography20. PNA oligomers were synthesized on solid support
using Boc chemistry16. The oligomers were synthesized on MBHA (4-methylbenzhy-
drylamine) resin according to standard procedures of Boc chemistry. Kaiser test was
performed at each step to measure complete coupling and double coupling was
performed if it was required. The oligomers were cleaved from the resin using an
m-cresol/thioanisole/TFMSA/TFA (1:1:2:6) cocktail, and the resulting mixtures were
precipitated with ethyl ether, puriﬁed by reversed phase-high-performance liquid
chromatography (acetonitrile:water) and characterized with a matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometer.
The sequences of PNAs used in this study are given in Fig. 1. The single-
stranded donor DNA oligomer was prepared by standard DNA synthesis except for
the inclusion of three phosphorothiate internucleoside linkages at each end to
protect from nuclease degradation. The sequence of the donor DNA matches
positions 624–684 in b-globin intron 2 and is as follows, with the correcting
IVS2-654 nucleotide underlined: 50AAAGAATAACAGTGATAATTTCTGGGTT
AAGGCAATAGCAATATCTCTGC ATATAAATAT30 .
For gene editing experiments in the human CD34þ studies, the donor DNA
was designed to introduce rather than correct the IVS2-654 mutation, and so the
sequence of the donor was:
50-AAAGAATAACAGTGATAATTTC TGGGCGTTCTCAATAGCAATATC
TCTGCATATAAATAT-30. Note that besides the IVS2-654 mutation, this donor
was designed to introduce 5 other point mutations adjacent to the IVS2-654 bp
(underlined) to further facilitate detection by deep sequencing.
PLGA nanoparticle synthesis and characterization. PLGA nanoparticles
containing PNAs and DNAs were formulated using a double-emulsion solvent
evaporation method and characterized PLGA nanoparticles encapsulating
PNA/donor DNA were formulated using a double-emulsion solvent evaporation
technique. PNAs and donor DNAs were dissolved in 60.8 ml DNAse-free water.
All nanoparticle batches had 2 nmolemg 1 of PNA or gPNA and 1nmolemg 1
of donor DNA. The encapsulant was added dropwise to a polymer solution
containing 80mg 50:50 ester-terminated PLGA dissolved in dichloromethane
(800 ml), then ultrasonicated (3 10 s) to formulate the ﬁrst emulsion. To form the
second emulsion, the ﬁrst emulsion was added slowly dropwise to 1.6ml of 5%
aqueous polyvinyl alcohol and then ultrasonicated (3 10 s). This mixture was
ﬁnally poured into 20ml of 0.3% aqueous polyvinyl alcohol and stirred for 3 h at
room temperature. Nanoparticles were then thoroughly washed with 20ml water
(3 ) and further collected each time by centrifugation (12,000 r.p.m. for 10min at
4 C). Nanoparticles were resuspended in water, frozen at  80 C, and then
lyophilized. Nanoparticles were stored at  20 C after lyophilisation21.
Nucleic acid release was analysed by incubating nanoparticles (4–6mg) in
Table 2 | Off-target effects in bone marrow cells following intravenous treatment of b-thalassemic mice with SCF and gtcPNA4/
donor DNA NPs.
Gene locus Sequences of partial homology
(50–30)
Size of region
sequenced
Alleles
sequenced
Number
modiﬁed
Frequency
(%)
b-globin TGCCCTGAAAGAAAGAGA 128 8,615,313 337,192 3.9
Vascular cell adhesion protein
precursor 1
AGCCCTGAAAGAAAGAGA 111 482,051 0 0
Polypyrimidine tract binding protein GAACCTGAAAGAAAGAGA 101 355,567 2 0.00056
Protocadherin fat 4 precursor CACCCTGAAAGAAAGAAG 115 123,158 0 0
Olfactory receptor 266 AAGCCTGAAAGAAAGATT 172 1,099,880 262 0.0231
Syntaxin binding protein AGAAATGAAAGAAAGAGA 150 2,493,024 0 0
Muscleblind like protein GGTGGTGAAAGAAAGAGA 165 2,336,715 0 0
Ceruloplasmin isoform AGGACTGAAAGAAAGAGT 154 1,397,271 0 0
Total off-target 8,287,666 268 0.0032
The top seven gene loci in the mouse genome with partial homology to the 18 bp gtcPNA4 target site in b-globin intron 2 were identiﬁed, with the sequences as indicated. Thalassemic mice were treated
with SCF followed by intravenous infusion with NPs containing gtcPNA4/donor DNA, and genomic DNA from c-Kitþ BM cells was subject to deep sequencing analysis at these loci. The size of the
region sequenced around each site is listed, along with the number of alleles sequenced and the number of alleles with modiﬁed sequences.
Table 3 | Deep sequencing analysis of targeted gene editing versus off-target effects in human CD34þ haematopoietic cells
following ex vivo treatment with SCF and gtcPNA4/donor DNA NPs.
Gene locus Sequences of partial
homology
(50–30)
Size of region
sequenced
Alleles
sequenced
Number
modiﬁed
Frequency
(%)
b-globin TGCCCTGAAAGAAAGAGA 128 12,489,910 606,230 5.02
Serine Theronine Kinase ATTCCTGAAAGAAAGCAC 189 3,330,879 0 0
Anoctamin-3 AATTCTGAAAGAAAGACC 150 5,805,518 1 0.000017
39s Ribosomal protein L17 AGCCCTGAAAGAATACCA 169 4,211,251 0 0
Neuroblast differentiation
associated
TCCCTGAAAGAAAAAAGA 198 3,579,389 2 0.000055
Transcription enhance factor TEF1 TCTCCCTGAAAGAAAAAA 244 80,548 0 0
Rho GTPase activating protein CAACATGAAAGAAAGAGA 154 8,256,220 0 0
Total off-target 25,263,805 3 0.000012
The top six gene loci in the human genome with partial homology to the 18 bp gtcPNA4 target site in b-globin intron 2 were identiﬁed, with the sequences as indicated. Human CD34þ haematopoietic
cells were treated ex vivo with SCF and with NPs containing gtcPNA4/donor DNA, and 2 days later genomic DNA from the cells was subject to deep sequencing analysis at these loci. The size of the
region sequenced around each site is listed, along with the number of alleles sequenced and the number of alleles with modiﬁed sequences.
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phosphate-buffered saline (PBS; 600ml) in a 37 C shaker, spinning down
and removing supernatant. Further absorbance of the supernatant was measured
at 260 nm at the indicated time points. At 24 and 48 h nanoparticles, the
residual nucleic acid in the nanoparticle pellet was extracted and total nucleic
acid content was calculated as a sum of absorbance obtained from the pellet as
well as supernatant. Absorbances at 260 nm were measured with a Nanodrop
2,000 (ref. 21).
Ex vivo experiments with BM cells from b-globin/GFP mice. BM cells were
harvested by ﬂushing femurs and tibias of b-globin/GFP transgenic mice with
Roswell Park Memorial Institute (RPMI)/10% foetal bovine serum (FBS) media.
Nanoparticles (2mgml 1) were used to treat B300,000–500,000 cells for 48 h in
RPMI/10% FBS media containing glutamine, in triplicate samples. After 48 h, cells
were ﬁxed with 4% paraformaldehyde, and analysed by ﬂow cytometry. Cells
treated with blank nanoparticles were included as a control.
For experiments with CD117þ , cells were isolated by magnetic separation and
grown in cells, Iscove’s Modiﬁed Dulbecco’s Media media containing insulin
(10 ngml 1), FCS (10%) and erythropoietin (1Uml 1). Where indicated,
3 mgml 1 of SCF (recombinant murine SCF, catalogue #250-03, PeproTech,
Rocky Hill, NJ;) was added before nanoparticle treatment. NPs ( 2mgml 1) were
used to treat 50,000–100,000 CD117þ cells in triplicate for 48 h in the above
media, followed by ﬂow cytometry analyses as above. Inhibitors were used at
concentrations of 200 nM (dasatinib), 1.0 mM (MEK162) and 3.0 mM (BKM120).
Dasatanib was obtained from Cayman Chemical (Ann Arbor, MI; item #11498)
and dissolved according to manfacturer’s protocol. MEK162 and BKM120 were
obtained from Dr. Harriet Kluger, Yale University.
Sorting and ﬂow cytometry of cells from b-globin/GFP mice. BD Bioscience kit
catalogue #558451 (BDImag Haematopoietic Progenitor Stem Cell Enrichment
Set—DM) was used to isolate CD117 cells. Enrichment for CD117 was conﬁrmed
by ﬂow cytometry. CD117þ enriched cells were labelled with CD117-APC
(BD Pharmingen catalogue #558451) antibody used a dilution of 1:100. Cells were
co-labelled with control IgG antibody (BD Pharmingen catalogue #555746 used a
dilution of 1:100) for gating purposes. To quantify GFP expression, after CD117
co-labelling, ﬂow cytometry was performed using FACScaliburS by resuspending
cells in PBS/1%FBS where green ﬂuorescent cells are measured in the Fl1 channel
and APC stained cells are in the Fl4 channel. Antibodies for other markers were
Ter119 (BD Pharmingen catalogue #561033) and CD45 APC (BD Pharmingen
catalogue #561018), both used a dilution of 1:100. See below for isolation of
progenitor cell populations from thalassemic mice.
DNA binding gel shift assays. For gel electrophoresis, synthetic 120 bp dsDNA
targets were incubated with indicated oligomers at 37 C in low ionic strength
buffer (10mM NaPi, pH 7.4). The samples were separated on 10% non-denaturing
polyacrylamide gels in 1 TBE buffer. The gels were run at 100V cm 1 for 1.5 h.
After electrophoresis, the gels were stained with 1 SYBR-Gold (catalogue
#S11494, Invitrogen) for 10min, washed 2 with 1 TBE buffer, and then
imaged using a gel documentation system (BioDoc-It System). The images were
then inverted using Adobe Photoshop 6.0.
Comet assay. 400,000 BM cells per well were plated on 6-well plates in 1ml
media, then treated with 2mgml 1 of either blank NPs or PLGA NPs containing
either tcPNA1/donor DNA, gtcPNA4/donor DNA or bleomycin/donor DNA, as
indicated in Supplementary Fig. 4. After 48 h, cells were harvested, and prepared
using the Trevigen Comet Assay kit per manufacturer’s protocol (Trevigen,
Gaithersburg, MD). Brieﬂy, cells were suspended in agarose, added to comet slides,
allowed to set, incubated 1 h in lysis solution, placed in electrophoresis solution for
30min, then run at 21V for 45min, placed in acetate solution for 30min,
transferred to 70% ethanol solution for 30min, dried, stained with Sybr Green for
30min and then visualized using an EVOS microscope. TriTek Comet Score
freeware was used to analyse images.
Reporter gene assay for homology-dependent repair. An inactivating I-Sce1
site was cloned 56 amino acids into the ﬁreﬂy luciferase open reading frame under
the control of a cytomegalovirus (CMV) promoter. The reporter construct also
contains a promoterless luciferase gene used as a template for homologous
recombination. A DSB in the luciferase reporter is created by in vitro digestion with
the I-Sce I restriction enzyme (NEB # R0694L). Plasmid DNA was digested with
I-Sce 1 for 1 h at 37 C at a ratio of 10 units enzyme to 1 mg DNA and then the
enzyme was inactivated at 65 C for 20min. The linearization of the plasmid was
conﬁrmed for each digestion via gel electrophoresis and the linear plasmid was
puriﬁed using the Qiagen Qiaquick spin columns. After separation, CD117þ and
CD117-cells from BM of b-globin/GFP transgenic mice, cells were transfected
using the Lonza 2b Nucleofector Device. 5 105 cells were transfected with 1 mg of
either the luciferase reporter vector or a positive control ﬁreﬂy luciferase expression
vector, along with 50 ng of a renilla luciferase expression plasmid as a transfection
efﬁciency control. All transfections were performed in triplicate. After transfection
the cells were plated at a density of 5 105 cells per ml in 12-well plates. After 24 h
incubation post transfection, luciferase activity was measured using the Promega
Dual Luciferase Assay Kit. In each sample ﬁreﬂy luciferase activity was normalized
to the renilla luciferase transfection control. Reporter reactivation was calculated as
a ratio of normalized ﬁreﬂy luciferase activity in the cells transfected with the
reporter plasmid to the positive control.
Mouse models and in vivo treatments. All animal use was in accordance with
the guidelines of the Animal Care and Use Committee of Yale University and
conformed to the recommendations in the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources, National Research
Council, National Academy of Sciences, 1996).
The b-globin/GFP transgenic mice were obtained from Ryszard Kole,
University of North Carolina19. For treatment of the mice, where indicated SCF
(220 mg kg 1 per mouse, Recombinant Mouse SCF, carrier-free, R&D catalogue
#455-mc-050/CF) was injected intraperitoneally 3 h before treatment with 4mg of
NPs in 150 ml PBS delivered via retro-orbital intravenous injection. In some cases,
mice were killed 48 h after the NP injections, and BM and spleen cells were
harvested for further analysis. The BM and spleen cells (500,000 each) were
co-labelled with APC conjugated antibodies as described above and ﬂow cytometry
was performed as above. For deep sequencing analyses, CD117þ cells were
isolated by magnetic separation using a BD Bioscience protocol (BDImag
Hematopoietic Progenitor Stem Cell Enrichment Set—DM). Genomic
DNA from three mice was pooled followed by sequence analysis as previously
described12.
The IVS2-654 b-thalassemic mice were obtained from Ryszard Kole, University
of North Carolina18. For in vivo experiments, where indicated, SCF (220mg kg 1 per
mouse, Recombinant Mouse SCF, carrier-free, R&D catalogue #455-mc-050/CF) was
injected intraperitoneally 3 h prior to treatment with 4mg of NPs in 150ml of PBS
delivered via retro-orbital intravenous injection. Each mouse received four
treatments given at 48 h intervals. Mice were anesthetized with isoﬂurane followed
by retro-orbital bleeding (B100ml) using ethylenediaminetetraacetic acid–treated
glass capillary tubes. The blood was evacuated into tubes with 5ml of 0.5 M EDTA
acid in heparinized coated tubes. Complete blood counts were performed using a
Hemavet 950FS (Drew Scientiﬁc, Oxford, CT) according to the manufacturer’s
protocol. Slides containing blood smears were stained with Wright and Giemsa stain
for microscopy. Methylene blue staining was used for reticulocyte counts. Spleen
images and weights were taken after selected mice were killed on day 36 after the last
treatment. Harvested spleens were ﬁxed in 10% neutral buffered formalin and
processed by Yale Pathology Tissue Services for H&E, CD61 and E cadherin staining.
For assigning animals into treatment groups as listed above, littermate
animals were genotyped, and then the pups carrying the required genotypes
(either b-globin/GFP transgenic mice or IVS2-654 b-thalassemic mice) were
randomized into the several treatment groups in cohorts of 3–6, as indicated, at 8
weeks of age. Both genders were included. The investigators were not blinded as to
treatment groups.
Deep sequencing analyses. Genomic DNA from mouse cells treated ex vivo or
from cell from mice treated in vivo, as indicated, was harvested using the Wizard
Genomic Puriﬁcation Kit (Promega), and then electrophoresed in a 1% low melting
point agarose gel in TAE, to separate genomic DNA from possible residual PNA
and/or DNA oligonucleotide. The high-molecular weight species, representing
genomic DNA, was cut from the agarose gel and extracted using the Wizard SV Gel
and PCR Clean-Up System (Promega) according to manufacturer’s instructions.
Once genomic DNA was isolated from treated cells or mouse tissue, PCR reactions
were performed with high ﬁdelity TAQ polymerase. Each PCR tube consisted of
28.2 ml dH2O, 5 ml 10 HiFi Buffer, 3 ml 50mM MgCl2, 1 ml DNTP, 1 ml each of
forward and reverse primer, 0.8 ml High Fidelity Platinum Taq Polymerase
(Invitrogen, Carlsbad, CA) and 10 ml DNA template. PCR products were prepared
by end-repair and adaptor ligation according to Illumina protocols (San Diego,
CA), and samples sequenced by the Illumina HiSeq with 75 paired-end reads at the
Yale Center for Genome Analysis. Samples were analysed as previously described12.
Primers for deep sequencing were designed using Primer3 database. The primers
used for b globin intron 2 were as follows: forward primer: 50-TATCATGCC
TCTTTGCACCA-30 ; reverse primer: 50-AGCAATATGAAACCTCTTACATC
A-30 . Primers for off-target sites of partial homology were as follows; forward
primer is listed ﬁrst: vascular cell adhesion protein precursor 1 (50-AGATAATTAT
TGCCTCCCACTGC-30 and 50-AATGGAAGGGCATGCAGTCA-30);
polypyrimidine tract binding protein (50-CCCAATCCTGAATCCTGGCT-30
and 50-CATACTGATGTCTGTGGCTTGA-30); protocadherin fat 4 precursor
(50-AAGCTCAAACCTACCAGACCA-30 and 50-AGCTGGAAGCTTCTTCAG
TCA-30); olfactory receptor 266 (50-CCCTCTGTGGACTGAGGAAG-30 and 50-TG
ATGAGCTACGGGTATGTGA-30); syntaxin binding protein (50-CAAAAAGCCT
TAAGCAAACACTC-30 and 50-TCTCTCCCTCAGCATCTATTCC-30);
muscleblind-like protein (50-TGTGTTTGTTTATGGATACTTGAGC-30 snd 50-G
CATGCACAATAAAGGCACT-30); ceruloplasmin isoform (50-CATGGGAAAC
AGTCAAAAGAAA-30 and 50-TGTAGGTTTCCCCACAGCTT-30).
Cytokine array analysis. NPs (4.0mg) containing gtcPNA4/donor DNA were
injected i.v. into b-globin/GFP transgenic mice. After, and after 48 h, plasma
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samples were collected. Cytokine array analyses were performed on 25.0 ml of
plasma and analysed for cytokines using the luminex based cytokine detection
and quantiﬁcation technology at the CytoPlex Core Facility at Yale University
(https://medicine.yale.edu/obgyn/drs/immunology/).
Analysis of HSCs from BM of treated thalassemic mice. Thalassemic mice were
treated as above with four treatments of NPs atat 2 day intervals of 4mg of NPs in
150ml PBS delivered via retro-orbital intravenous injection along with SCF given i.p.
Sixty-ﬁve days later, mouse tibias and femurs were collected and crushed in mortar
with 5ml ﬂuorescence-activated cell sorting (FACS) buffer (PBSþ 0.5% bovine
serum albuminþ 2mM EDTA). The BM was passed through a 100m cell strainer
and then the cells were collected by centrifugation at 250g for 5min at room
temperature. The cell pellets were resuspended in 5ml of RBC lysis buffer for 1min.
The suspensions were diluted with 1ml FBS and 14ml FACS buffer, cells were
collected by centrifugation, and then resuspended in FACS buffer for antibody
staining, followed by FACS. Antibodies used were as follows: from BD Biosciences
(www.bdbiosciences.com): BD553086 (CD45R/B220), BD553309 (CD11b),
BD553672 (Ter119), BD553060 (CD3e), BD553028 (CD8a), BD553649 (CD4);
BD562729-Ly-6A/E (Sca1), BD565502-CD16/CD32 (FcgR); from BioLegend
(http://www.biolegend.com): APC c-Kit (BioLegend 105812-CD117), CD105
(BioLegend 120406-CD105), PE-Cy5CD135 (BioLegend 135312-CD135), PE-CD150
(BioLegend 115904-CD150 SLAM), PE/Cy7 Streptavidin (BioLegend 405206-
Biotin). Antibodies were used at 0.2–0.8mgml 1. From isolated cell populations,
genomic DNA extraction was performed using the Wizard Genomic Puriﬁcation Kit
(Promega) and samples were submitted for deep sequencing as above.
PCR with reverse transcription analysis. Cells were harvested, pelleted and
frozen in RNA stabilization reagent (Qiagen), until ready for RNA extraction. RNA
was extracted from the cell pellets using the RNAeasy Mini Plus kit from Qiagen, as
per the manufacturer’s protocol. The Invitrogen SuperScript III kit was used to
generate cDNA from the RNA, as per the manufacturer’s protocol, using 500 ng of
RNA per reaction. PCR reactions contained cDNA, 20% Betaine, 0.2mM dNTPS,
Advantage 2 Polymerase Mix, 0.2 mM of each primer, 2% Platinum Taq, and
Brilliant SYBR Green. Primers and ROX reference dye were obtained from
Stratagene and analysis was conducted using a Mx3000p realtime cycler. Cycler
conditions were 94 C for 2min, 40 cycles of 94 C 30 s/50 C 30 s/72 C 1min,
then 95 C for 1min. Relative expression were calculated using the 2DDCt method
(Cto36) and then normalized. Mouse BRCA2 primers were designed using
Primer3 database: BRCA2-3F: 50-GTTCATAACCGTGGGGCTTA-30 and
BRCA2-3R: 50-TTGGGAAATTTTTAAGGCGA-30 . For BRCA2 data analysis
GAPDH were used as control using following primers: 50-TGATGACATC AAG
AAGGTGGTGAAG-30 and 50-TCCTTGGAGG CCATGTGGGCCAT-30 . For
RAD51 analysis, Rad51 mRNA was quantiﬁed by using TaqMan Gene
Expression Assay (Life technologies, Mm00487905_m1) kit and using gene 18S
(Life technologies, Mm03928990_g1) as a control.
Western blot analysis. CD117þ and CD117-cells were isolated from
b-globin/GFP mice and protein was extracted with Radio-Immunoprecipitation
Assay lysis buffer. Total protein of 50–100 mg was run on SDS/polyacrylamide gel
electrophoresis gels and transferred to nitrocellulose membranes. Antibodies used
were: Anti-BRCA2 (Ab-1) mouse mAb (EMD Millipore, OP95-100 ug) at 1:10,000
anti-RAD51-antibody (Santa Cruz biotechnology, SC 8349) at 1:10,000.
Microarray analysis. Microarray analyses were performed on CD117þ and
CD117-cells obtained from BM of three separate b-globin/GFP mice at Yale Center
of genomic analysis at Yale west campus. Each replicate cell sample was obtained
from a separate mouse. RNA was extracted from 2 106 for each sample using the
RNeasy Mini Plus kit from Qiagen, as per the manufacturer’s protocol. Following
DNase treatment, total RNA was sequenced and analysed at the Yale Center for
Genome Analysis. Heat maps were generated using variance stabilizing transforma-
tions of the count data on the basis of a parametric ﬁt to the overall mean dispersions.
cH2AX foci experiments. Samples of 20,000 BM cells each from b-gobin/GFP
mice were either untreated or were treated with 2mgml 1 of NPs containing
gtcPNA4 and donor DNA or with 5 Gy IR, as indicated in Supplementary Fig. 4F.
After 48 h, cells were washed with PBS, ﬁxed in 70% ice-cold ethanol, washed
again with PBS and incubated for 15min on ice in PBST buffer (PBS containing
1% bovine serum albumin and 0.2% Triton X-100). Cells were collected by
centrifugation and incubated with an anti-phospho-H2AX antibody
(Cell Signaling, #9718) diluted at a ratio of 1:200 in PBST buffer overnight at 4 C.
Cells were washed and incubated with an anti-rabbit antibody conjugated with
Alexa 488 (Cell Signaling, #4412) diluted at a ratio of 1:100 in PBST buffer, and
incubated for 1 h in the dark at room temperature. Cells were washed and
resuspended in PBS for ﬂow cytometry analysis.
For the primary ﬁbroblasts from the b-globin/GFP mice, 50 103 cells were
pretreated with the indicated reagents in Fig. 1h,i for 48 h in chamber well slides
(Millipore Millicell EZ Slides). Selected samples were irradiated with 5Gy IR as a
positive control. Cas9 and guide RNA (designed to bind to the same site in
b-globin gene as gtcPNA4) expression plasmids were obtained from GeneCopoeia
(www.genecopoeia.com). Cas9 and guide RNA expression plasmids were
transfected using lipofectamine (Thermo Fisher Scientiﬁc; www.thermoﬁsher.com),
per manufacturer’s instructions, either as separate expression vector plasmids
(Cas9þ gRNA) or contained on the same plasmid (Cas9 and gRNA). Cas9 and
gRNA of 1.3 mg were added into each well for 48 h, as indicated. Cells were ﬁxed
with 1% paraformaldehyde/2% sucrose for 15min at room temperature, followed
by 100% methanol for 30min at  20 C and 50% methanol/50% acetone for
20min at  20 C. Slides were then incubated in permeabilization/blocking
solution (10% BGS, 0.5% Triton X-100 in PBS) at room temperature for 1 h.
Primary antibody (phospho-speciﬁc H2A.X (Cell Signaling #9718S)) was diluted
1:500 in permeabilization/blocking solution and used to stain cells at 4 C
overnight. The secondary antibody used was Alexa Fluor 488-conjugated goat
anti-rabbit immunoglobulin G (IgG; Life Technologies). Cells were costained with
DAPI to visualize the nuclei.
Cell cycle analysis. Pre-sorted CD117 cells were treated with SCF for 48 h and then
ﬁxed in 70% ethanol, treated with 100mgml 1 RNase, and stained with propidium
iodide. Cells were analysed by ﬂow cytometry using 10,000 cells per condition.
Treatment and analysis of human CD34þ cells. Human CD34þ cells were
obtained from the Yale Center of Excellence in Molecular Hematology
(Yale University, New Haven, CT) from granulocyte colony-stimulating factor-
mobilized peripheral blood of normal healthy donors. Cells were received frozen,
thawed, pooled and maintained in StemSpan serum-free expansion medium
(SFEM) with StemSpan CC100 cytokine mixture (Stemcell Technologies,
Vancouver, British Columbia, Canada). Cell counts were performed with a Nex-
celcom Cellometer Auto T4 (Bioscience, Lawrence, MA). CD34 cells (6 105) were
treated with SCF (1.0 mg) and 2.0mg of nanoparticles containing gtcPNA4/donor
DNA in the SFEM with the CC100 cytokine mixture for 48 h. Cells were harvested,
and genomic DNA extraction was performed using the Wizard Genomic
Puriﬁcation Kit (Promega). Samples were submitted for deep sequencing as
above. For off-target analyses for the human DNA, the primers used were: serine
threonine kinase (50-TTTCTTGCCATGTTGGTGTG-30 and 50-CCTCCGGTCCT
ATTTGTTCA30), anoctamin-3 (50-TTGCATTTATTGGCAGCTTT30&and
50-TTCAGTGATTAAATTCTGTCACTCTG30), 39s Ribosomal protein L17
(50-TGCACTTATTAATCACCAACTCTG30 and 50-TGGCCCTTTGATATAG
CTGTG30), neuroblast differentiation associated protein (50-AGGTGGGCAACA
TCAATTTC30 and 50-CAGGCCCAGCATCTTGTATT30), transciption enhancer
factor TEF1 (50-TGCCAACACAGTGCTTTCTC30 and 50-GAGCTTTGTGAAGG
CAGGAC30), RhoGTPase activating protein (50-AAGCTAAACGGTGTCTCT
TTCTG30 and 50-GCATCATGGATCTGATTTGC30).
For cytokine array analysis, after NP treatment of the CD34þ cells, as above,
supernatant medium was collected and analysed by a luminex based assay as
describe above.
Transplantation of treated human CD34þ cells. Human CD34 cells (6 105)
were treated, as above, with SCF (1.0 mg) and 2.0mg of nanoparticles containing
gtcPNA4/donor DNA in the SFEM with the CC100 cytokine mixture for 48 h
and then were used to transplant immunodeﬁcient recipient NOD-scid IL2rgnull
mice. As above, all animal use was in accordance with the guidelines of the
Institutional Animal Care and Use Committees (IACUC) of the University of
Massachusetts Medical School, Yale University, and The Jackson Laboratory.
NOD.Cg-PrkdcscidIL2rgtm1Wjl (abbreviated NOD-scid IL2rgnull) mice were
obtained from the research colony maintained at The Jackson Laboratory.
Transplant of treated CD34 cells into the NOD-scid IL2rgnull mice was performed
by intracardiac injection into newborn mice as previously described12. Engraftment
was conﬁrmed at 7 weeks. Eight weeks post transplant, human CD34þ cells were
isolated from mouse BM using EasySep human CD34þ positive selection Kit
(StemCell Technologies; Cat# 18056). Genomic DNA was extracted from CD34þ
cells using the Wizard Genomic Puriﬁcation Kit (Promega). Samples were
submitted for deep sequencing as described above.
Data availability. Microarray data have been deposited in Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) under accession
code GSE86859.
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